BerGenBio ASA (BGBIO.OL)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Rune Skeie | Chief Financial Officer | 2.68M | -- | 1973 |
| Ms. Cristina Oliva M.D. | Chief Medical Officer | 5.31M | -- | -- |
| Mr. Olav Hellebo BBA, MBA | Chief Executive Officer | -- | -- | 1965 |
| Graham Morell | Head of IR | -- | -- | -- |
| Ms. Gayle M. Mills M.B.A | Chief Business Officer | -- | -- | 1955 |
| Dr. Akil Jackson | Medical Director | -- | -- | -- |
BerGenBio ASA
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 13
Description
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat drug resistant, metastatic cancers, and respiratory diseases in Norway. The company's lead clinical asset is the Bemcentinib (BGB016), an inhibitor of AXL receptor tyrosine kinase (AXL), which is in phase 1b/2a clinical trial to treat non-small cell lung cancer; and (BGBC008), which is in phase 2 clinical trial to treat second-line non-small cell lung cancer (2L NSCLC). It develops Bemcentinib, which is in preclinical trial to treat acute respiratory distress syndrome; Tilvestamab (BGB149), anti-AXL monoclonal antibody, which in phase 1 clinical trial for the treatment of ovarian cancer; and Mipasetamab Uzoptirine, which is in Phase 1 clinical trial for the treatment of solid tumors. BerGenBio ASA was incorporated in 2007 and is based in Bergen, Norway.
Corporate Governance
Upcoming Events
May 21, 2025 at 5:00 AM UTC
BerGenBio ASA Earnings Date
Recent Events
Recent Events Information Not Available